DEBIO‐0932, a second‐generation inhibitor of HSP90 with the ability to penetrate the BBB (Bao et al, 2009), is currently under evaluation in a Phase I/II study for patients with advanced NSCLC (NCT01714037). The gene discussed is HSP90AA1; the disease is non-small cell lung carcinoma.